StreetAlpha.app
Home › Stocks › COLL

Collegium Pharmaceutical, Inc (COLL)

Healthcare
$25.55
▲ +0.47%
LAST CLOSE · NOV 17

Collegium Pharmaceutical sells prescription medicines for ADHD and pain in the United States. It last closed at $25.55 on Nov 17, up 0.47% on the day. The average 12-month price target from 6 analysts is $42.83 (+67.6% from the last close), with a high of $50.00 and a low of $28.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (5 buy, 1 hold, 0 sell).

AI Auto Pilots
Is COLL in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$815.2M
+7.7% vs a year ago
Net income
$38.2M
−34.7% vs a year ago
EPS (diluted)
$1.09
−33.1% vs a year ago
Free cash flow
$336.3M
41.3% margin
Valuation
Market cap
$794.0M
31.1M shares
P/E
23.4
Price over 12 month EPS
Price to sales
1.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$144.8M
At Sep 30
Debt
$239.0M
At Sep 30
Shareholder equity
$296.4M
Buybacks
$50.0M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $276.9M$276.9MFY2021FY2022: $463.9M$463.9MFY2022FY2023: $566.8M$566.8MFY2023FY2024: $631.4M$631.4MFY2024FY2025: $780.6M$780.6MFY2025

From COLL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
6firms
5 Buy1 Hold0 Sell
Each firm's latest rating on COLL in the past 90 days
Average 12-month target
$42.83
▲ 67.6% upside

Based on 6 analysts who set a price target on COLL in the past 90 days. The average target is $42.83, with a high of $50.00 and a low of $28.00, compared with the last close of $25.55.

Low $28.00Avg $42.83High $50.00
Blue marker: last close $25.55
Highest target$50.00
Average target$42.83
Lowest target$28.00
Latest rating changes
BarclaysTarget lowered
Nov 16Buy$48 → $41
Piper SandlerTarget lowered
Nov 6Hold$43 → $28
NeedhamTarget lowered
Nov 5Buy$46 → $44
OppenheimerInitiated
Sep 23Buy$50
Truist SecuritiesMaintained
Sep 9Buy$49
DateFirmActionRatingPrice target
Nov 16BarclaysTarget loweredBuy$48 → $41
Nov 6Piper SandlerTarget loweredHold$43 → $28
Nov 5NeedhamTarget loweredBuy$46 → $44
Sep 23OppenheimerInitiatedBuy$50
Sep 9Truist SecuritiesMaintainedBuy$49
Loading…

Technical Analysis

COLL · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend, nearing overbought

The stock is 6% above its 20 day and 10% above its 50 day average. It is 25% below its 200 day average, so the longer trend is down. Momentum is strong (RSI 66), near overbought. The nearest support is the swing low (Aug 12) at $25.47, and the nearest resistance the Pivot R1 at $25.81.

Short trendBullish
Long trendBearish
MomentumStrong
StretchNear overbought
VolatilityNormal, 3.5%/day
Key levels
$50.7952 week high+98.8%
$31.95200 day average+25.0%
$27.35100 day average+7.0%
$26.39Swing high (Nov 5)+3.3%
$25.81Pivot R1+1.0%
$25.55Last close
$25.47Swing low (Aug 12)−0.3%
$25.41Pivot−0.5%
$25.15Pivot S1−1.6%
$24.1220 day average−5.6%
$23.1250 day average−9.5%
$21.4352 week low−16.1%
Indicators
RSI (14)65.73Strong, overbought above 70Neutral
MACD0.58Above its signal lineBullish
Stochastic72.9Middle of its rangeNeutral
ADX (14)27.1Trending up
Williams %R-26.8Oversold below −80, overbought above −20Neutral
CCI (20)120.5Oversold below −100, overbought above 100Overbought
Rate of change+7.7%Change over 10 sessionsBullish
ATR (14)$0.88Typical daily range, 3.5% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for COLL

What happened before

See how COLL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow COLL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How COLL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in COLL in the last 90 days.

Loading…

See today’s whale options flow across the market →

COLL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼120 buying vs 164 selling
  • ▼Held by funds -16.8 pts
  • ▼Funds holding -42
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding240282−14.9%
In funds' top 1010–
Held by funds118.3%135.1%−16.8 pts
New / increased35 / 8543 / 122−27.3%
Reduced / sold out87 / 7782 / 31+45.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See COLL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether COLL is in one of them and how their past COLL trades turned out.

COLL in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered COLL in an article yet. Here's the latest on the wider market.

COLL Congress Trades

All congress trades →
Trades, 12 months
4
Buys
0
0%
Sells
4
100%
People
1
Last filed Sep 22
Who traded COLL · since 2026
Latest 4 filings
$15K – $50KTraded Aug 31, 2026Filed Sep 22, 2026
$15K – $50KTraded Jul 29, 2026Filed Sep 22, 2026
$1K – $15KTraded Jul 8, 2026Filed Sep 22, 2026
$1K – $15KTraded May 15, 2026Filed Jul 1, 2026
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchSell$15K – $50KAug 31, 2026Sep 22, 202622 d
Donald J TrumpExecutive branchSell$15K – $50KJul 29, 2026Sep 22, 202655 d
Donald J TrumpExecutive branchSell$1K – $15KJul 8, 2026Sep 22, 202676 d
Donald J TrumpExecutive branchSell$1K – $15KMay 15, 2026Jul 1, 202647 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Collegium Pharmaceutical

Collegium Pharmaceutical is a biopharmaceutical company based in Stoughton, Massachusetts. It sells prescription medicines in the United States for attention deficit hyperactivity disorder and for moderate to severe pain. Its products include Jornay PM for ADHD, Belbuca, Xtampza ER and the Nucynta products for pain, and Symproic for constipation caused by opioid use. Its customers are patients who receive these medicines through prescriptions written by doctors.

Headquarters
Stoughton, MA